Patents Assigned to SEN-JAM PHARMACEUTICAL INC.
  • Patent number: 11911355
    Abstract: The present invention provides a method of inhibiting tolerance to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: February 27, 2024
    Assignee: SEN-JAM PHARMACEUTICAL INC.
    Inventors: Jacqueline Iversen, Thomas A. Dahl
  • Patent number: 11883388
    Abstract: The present invention relates to a method of reducing or preventing the symptoms associated with the common cold. The method comprises administering to a subject an effective amount of a pharmaceutical composition before presenting with at least one symptom of the common cold. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, salts thereof, and combinations thereof.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: January 30, 2024
    Assignee: SEN-JAM Pharmaceutical Inc.
    Inventors: Jacqueline M. Iversen, Thomas A. Dahl
  • Patent number: 11793800
    Abstract: The invention relates to methods of inhibiting side effects associated with vaccination in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject before the subject is vaccinated, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine and cetirizine and combinations thereof.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: October 24, 2023
    Assignee: SEN-JAM PHARMACEUTICAL INC.
    Inventors: Jacqueline M. Iversen, Thomas A. Dahl